Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

FDA approval for Abeona's treatment targeting MPS IIIA marks a major regulatory and clinical-development milestone. The approval validates Abeona's foundational R&D efforts and creates a path to commercialization for a therapy addressing a rare disease with significant unmet patient need.